Depreciation & Amortization
The latest quarterly d&a is $0 with a quarter-over-quarter change of 0.00%. Depreciation and Amortization (D&A) is a non-cash expense that allocates the cost of tangible and intangible assets over their useful lives.
GF D&A
Reported quarterly depreciation and amortization; no daily interpolation.
Current D&A
$0
$0
Quarter-over-Quarter Change
0.00%
vs. $0 prior quarter
Historical Data
27
Quarters of data available
Quarterly D&A History
| Period | D&A | QoQ Change | % Change |
|---|---|---|---|
| Q2 2025 | $0 | +$0 | — |
| Q4 2024 | $0 | +$0 | — |
| Q2 2024 | $0 | +$0 | — |
| Q4 2023 | $0 | +$0 | — |
| Q2 2023 | $0 | +$0 | — |
| Q4 2022 | $0 | +$0 | — |
| Q2 2022 | $0 | +$0 | — |
| Q4 2021 | $0 | +$0 | — |
| Q2 2021 | $0 | +$0 | — |
| Q4 2020 | $0 | +$0 | — |
| Q2 2020 | $0 | +$0 | — |
| Q4 2019 | $0 | +$0 | — |
| Q2 2019 | $0 | +$0 | — |
| Q4 2018 | $0 | +$0 | — |
| Q2 2018 | $0 | +$0 | — |
| Q4 2017 | $0 | +$0 | — |
| Q2 2017 | $0 | +$0 | — |
| Q4 2016 | $0 | +$0 | — |
| Q2 2016 | $0 | +$0 | — |
| Q4 2015 | $0 | +$0 | — |
| Q2 2015 | $0 | +$0 | — |
| Q4 2014 | $0 | +$0 | — |
| Q2 2014 | $0 | +$0 | — |
| Q4 2013 | $0 | +$0 | — |
| Q2 2013 | $0 | +$0 | — |
| Q4 2012 | $0 | +$0 | — |
| Q2 2012 | $0 | — | — |
Related Metrics
About The New Germany Fund, Inc.
The New Germany Fund Inc. functions as a closed-ended equity investment vehicle, originally established by Deutsche Investment Management Americas Inc. and currently overseen by Deutsche Asset Management International GmbH. Its primary objective is to allocate capital within the public stock markets of Germany, seeking out opportunities in shares of companies operating across a diverse range of industries. The fund predominantly focuses its investments on small and mid-capitalization (SMC) firms. To assess its portfolio's returns, the fund utilizes the Midcap Market Performance Index as its benchmark. This fund was founded on January 16, 1990, and is legally registered in Germany.
- Sector
- Financial Services
- Industry
- Asset Management
- CEO
- Linda Lonneberg